Acarix Expands Investor Access with OTCQB Listing, Targets U.S. Market Growth

Acarix, a company specializing in medical devices for rapid coronary artery disease (CAD) assessment, has announced its listing on the OTCQB Market in the United States under the ticker symbol ACIXF. This strategic move aims to expand the company's investor base and support its growth in the U.S. market, which Acarix CEO Aamir Mahmood identifies as their most crucial commercial arena.

The OTCQB listing complements Acarix's existing presence on the Nasdaq First North Growth Market in Stockholm, potentially providing greater access and liquidity for U.S. investors interested in the company's innovative medical technology. Acarix's flagship product, the CADScor System, offers a non-invasive solution for healthcare providers to rule out CAD in patients experiencing chest pain, potentially reducing the need for more costly and invasive diagnostic procedures.

The CADScor System has received both CE approval for European markets and FDA DeNovo clearance in the United States, positioning Acarix to address a significant need in the healthcare industry. The company recently reported a substantial reorder of single-use patches for the CADScor System from a primary care clinic in the New Orleans metropolitan area, indicating growing adoption of the technology.

Further demonstrating market traction, Acarix has secured a multi-order for the CADScor System from Saving Grace Concierge, which plans to utilize the device as a diagnostic aid for symptomatic patients in the Oklahoma City and Tulsa metro areas. These developments suggest an increasing recognition of the CADScor System's potential to improve patient care and optimize healthcare resources.

Looking ahead, Acarix is focusing on several key areas to drive growth and market penetration. The company aims to boost top-line growth, advance reimbursement efforts with the Centers for Medicare & Medicaid Services (CMS) and private payers, and initiate new clinical trials. These initiatives are designed to further validate the CADScor System's efficacy and cost-effectiveness in real-world clinical settings.

Mahmood emphasized the significant potential for the CADScor System to reduce healthcare costs associated with unnecessary diagnostic procedures for CAD. By providing a quick, non-invasive method to rule out CAD at the point of care, the system could help streamline patient management and reduce the economic burden on healthcare systems.

The expansion of Acarix's presence in the U.S. financial markets through the OTCQB listing comes at a time when the healthcare industry is increasingly focused on innovative solutions to improve patient outcomes while managing costs. As the company continues to build its commercial presence in the United States, the additional visibility and access to investors provided by the OTCQB listing may play a crucial role in supporting its growth strategy.

For investors and industry observers, Acarix's progress in the U.S. market and its innovative approach to CAD assessment represent a noteworthy development in the medical device sector. The company's focus on non-invasive diagnostics aligns with broader trends towards patient-centric care and cost-effective healthcare solutions, potentially positioning Acarix for significant growth in the coming years.